Telomere Length in Relation to Immunological Parameters in Patients with Renal Cell Carcinoma

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Svenson, Ulrika ^a   Grönlund, Elisabeth ^b   Söderström, Ingegerd ^a   Sitaram, Raviprakash T ^a   Ljungberg, Börje ^a   Roos, Göran ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 7; INTERLEUKIN 8;

ADULT; ARTICLE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; KIDNEY CARCINOMA; KIDNEY CORTEX; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TELOMERE HOMEOSTASIS;

CARCINOMA, RENAL CELL; CYTOKINES; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-10; INTERLEUKIN-7; INTERLEUKIN-8; KIDNEY NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TELOMERE; TUMOR MARKERS, BIOLOGICAL;

EID: 84873258695     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055543     Document Type: Article

References (43)

1. Hug N, Lingner J, (2006) Telomere length homeostasis. Chromosoma 115: 413-425.
2. Greider CW, Blackburn EH, (1985) Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43: 405-413.
3. Cong YS, Wright WE, Shay JW, (2002) Human telomerase and its regulation. Microbiol Mol Biol Rev 66: 407-425.
4. Kaszubowska L, (2008) Telomere shortening and ageing of the immune system. J Physiol Pharmacol 59: 169-186.
5. Motzer RJ, Bander NH, Nanus DM, (1996) Renal-cell carcinoma. N Engl J Med 335: 865-875.
6. Eichelberg C, Junker K, Ljungberg B, Moch H, (2009) Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 55: 851-863.
7. Bisoffi M, Heaphy CM, Griffith JK, (2006) Telomeres: prognostic markers for solid tumors. Int J Cancer 119: 2255-2260.
8. Svenson U, Roos G, (2009) Telomere length as a biological marker in malignancy. Biochim Biophys Acta 1792: 317-323.
9. Heaphy CM, Meeker AK, (2011) The potential utility of telomere-related markers for cancer diagnosis. J Cell Mol Med 15: 1227-1238.
10. Svenson U, Nordfjäll K, Stegmayr B, Manjer J, Nilsson P, et al. (2008) Breast cancer survival is associated with telomere length in peripheral blood cells. Cancer Res 68: 3618-3623.
11. Svenson U, Ljungberg B, Roos G, (2009) Telomere length in peripheral blood predicts survival in clear cell renal cell carcinoma. Cancer Res 69: 2896-2901.
12. Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, et al. (2002) Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 62: 3876-3882.
13. Hu BT, Insel RA, (1999) Up-regulation of telomerase in human B lymphocytes occurs independently of cellular proliferation and with expression of the telomerase catalytic subunit. Eur J Immunol 29: 3745-3753.
14. Igarashi H, Sakaguchi N, (1997) Telomerase activity is induced in human peripheral B lymphocytes by the stimulation to antigen receptor. Blood 89: 1299-1307.
15. Kawauchi K, Ihjima K, Yamada O, (2005) IL-2 increases human telomerase reverse transcriptase activity transcriptionally and posttranslationally through phosphatidylinositol 3-kinase/Akt, heat shock protein 90, and mammalian target of rapamycin in transformed NK cells. J Immunol 174: 5261-5269.
16. Wallace DL, Bérard M, Soares MV, Oldham J, Cook JE, et al. (2006) Prolonged exposure of naïve CD8+ T cells to interleukin-7 or interleukin-15 stimulates proliferation without differentiation or loss of telomere length. Immunology 119: 243-253.
17. Frankenberger B, Noessner E, Schendel DJ, (2007) Immune suppression in renal cell carcinoma. Semin Cancer Biol 17: 330-343.
18. Griffiths RW, Elkord E, Gilham DE, Ramani V, Clarke N, et al. (2007) Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 56: 1743-1753.
19. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, et al. (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756-2761.
20. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
21. Viguier M, Lemaître F, Verola O, Cho MS, Gorochov G, et al. (2004) Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173: 1444-1453.
22. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, et al. (2005) Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65: 2457-2464.
23. Hirokawa K, Utsuyama M, Ishikawa T, Kikuchi Y, Kitagawa M, et al. (2009) Decline of T cell-related immune functions in cancer patients and an attempt to restore them through infusion of activated autologous T cells. Mech Ageing Dev 130: 86-91.
24. Ben-Baruch A, (2006) Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16: 38-52.
25. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, et al. (1997) The Heidelberg classification of renal cell tumours. J Pathol 183: 131-133.
26. Kokkonen H, Söderström I, Rocklöv J, Hallmans G, Lejon K, et al. (2010) Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 62: 383-391.
27. Nordfjäll K, Osterman P, Melander O, Nilsson P, Roos G, (2007) hTERT (-1327)T/C polymorphism is not associated with age-related telomere attrition in peripheral blood. Biochem Biophys Res Commun 358: 215-218.
28. Svenson U, Nordfjäll K, Baird D, Roger L, Osterman P, et al. (2011) Blood cell telomere length is a dynamic feature. PLoS One 6: e21485.
29. Fry TJ, Mackall CL, (2002) Interleukin-7: from bench to clinic. Blood 99: 3892-3904.
30. Lambeck AJ, Crijns AP, Leffers N, Sluiter WJ, ten Hoor KA, et al. (2007) Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res 13: 2385-2391.
31. Al-Rawi MA, Rmali K, Watkins G, Mansel RE, Jiang WG, (2004) Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer. Eur J Cancer 40: 494-502.
32. Xie K, (2001) Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12: 375-391.
33. Ménétrier-Caux C, Bain C, Favrot MC, Duc A, Blay JY, (1999) Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes. Br J Cancer 79: 119-130.
34. Wittke F, Hoffmann R, Buer J, Dallmann I, Oevermann K, et al. (1999) Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br J Cancer 79: 1182-1184.
35. Sellmann L, de Beer D, Bartels M, Opalka B, Nückel H, et al. (2011) Telomeres and prognosis in patients with chronic lymphocytic leukaemia. Int J Hematol 93: 74-82.
36. Wu KD, Orme LM, Shaughnessy J Jr, Jacobson J, Barlogie B, et al. (2003) Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood 101: 4982-4989.
37. Liu HQ, An JZ, Liu J, Yang YF, Zhang HX, et al. (2012) Leukocyte telomere length predicts overall survival in hepatocellular carcinoma treated with transarterial chemoembolization. Carcinogenesis 33: 1040-1045.
38. Facciabene A, Motz GT, Coukos G, (2012) T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 72: 2162-2171.
39. Rufer N, Brümmendorf TH, Kolvraa S, Bischoff C, Christensen K, et al. (1999) Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med 190: 157-167.
40. Hoffmann J, Erben Y, Zeiher AM, Dimmeler S, Spyridopoulos I, (2009) Telomere length-heterogeneity among myeloid cells is a predictor for chronological ageing. Exp Gerontol 44: 363-366.
41. Aubert G, Baerlocher GM, Vulto I, Poon SS, Lansdorp PM, (2012) Collapse of telomere homeostasis in hematopoietic cells caused by heterozygous mutations in telomerase genes. PLoS Genet 8: e1002696.
42. Weng NP, Levine BL, June CH, Hodes RJ, (1995) Human naive and memory T lymphocytes differ in telomeric length and replicative potential. Proc Natl Acad Sci U S A 92: 11091-11094.
43. Rufer N, Dragowska W, Thornbury G, Roosnek E, Lansdorp PM, (1998) Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat Biotechnol 16: 743-747.